Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | FABP1 | P07148 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5242616 | 0.87 | HSD11B1 (0.47) | HSD11B1ALDH1A1GAAFABP1ACHE | |
| SCHEMBL5242720 | 0.84 | ALDH1A1 (0.67) | ALDH1A1GAAFABP1L3MBTL1ALOX15 | |
| SCHEMBL5242913 | 0.82 | HSD11B1 (0.57) | HSD11B1ALDH1A1KDM4ETDP1 | |
| SCHEMBL5244145 | 0.82 | L3MBTL1 (0.50) | ALDH1A1GAAFABP1L3MBTL1ALOX15 | |
| SCHEMBL4787514 | 0.82 | L3MBTL1 (0.52) | ALDH1A1GAAFABP1L3MBTL1ALOX15 | |
| SCHEMBL4787536 | 0.81 | ALDH1A1 (0.55) | ALDH1A1GAAL3MBTL1ALOX15KDM4E | |
| SCHEMBL5242949 | 0.81 | ALDH1A1 (0.53) | ALDH1A1GAAFABP1L3MBTL1ALOX15 | |
| SCHEMBL4788475 | 0.81 | KMT2A (0.57) | HSD11B1ALDH1A1GAAL3MBTL1KDM4E | |
| SCHEMBL4786255 | 0.79 | L3MBTL1 (0.48) | ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL5245687 | 0.79 | HSD11B1 (0.52) | HSD11B1ALDH1A1GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | claimed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | HSD11B1 3974/4885ALDH1A1 2627/4885GAA 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.